- Home
- BMRN
as 05-20-2024 11:33am EST
$.
-
$.
-.%
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | NOVATO |
| Market Cap: | 15.8B | IPO Year: | 1999 |
| Target Price: | $105.90 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 22 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.06 | EPS Growth: | 178.95 |
| 52 Week Low/High: | $76.02 - $99.56 | Next Earning Date: | 04-24-2024 |
| Revenue: | $2,471,644,000 | Revenue Growth: | 13.74% |
| Revenue Growth (this year): | 16.4% | Revenue Growth (next year): | 14.70% |
Share on Social Networks:
Stock Insider Trading Activity of BioMarin Pharmaceutical Inc. (BMRN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Davis George Eric | BMRN | EVP, Chief Legal Officer | May 2 '24 | Sell | $85.01 | 1,850 | $157,268.50 | 56,157 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Apr 11 '24 | Sell | $90.99 | 20,000 | $1,819,800.00 | 474,994 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Apr 11 '24 | Sell | $91.26 | 20,000 | $1,825,200.00 | 474,994 | SEC Form 4 |
| Burkhart Erin | BMRN | GVP, Chief Accounting Officer | Apr 10 '24 | Sell | $90.00 | 2,286 | $205,740.00 | 16,156 | SEC Form 4 |
| FUCHS HENRY J | BMRN | President, Worldwide R&D | Mar 5 '24 | Sell | $85.18 | 35,341 | $3,010,395.86 | 212,117 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Mar 5 '24 | Sell | $85.51 | 1,000 | $85,510.00 | 561,203 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Mar 5 '24 | Sell | $86.71 | 1,000 | $86,713.00 | 560,203 | SEC Form 4 |
| Ajer Jeffrey Robert | BMRN | EVP, Chief Commercial Officer | Mar 5 '24 | Sell | $87.07 | 4,000 | $348,280.00 | 94,047 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Jan 18 '24 | Sell | $89.77 | 15,000 | $1,346,550.00 | 419,602 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Jan 18 '24 | Sell | $88.28 | 15,000 | $1,324,200.00 | 419,602 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Jan 8 '24 | Sell | $96.38 | 10,000 | $963,800.00 | 425,162 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Jan 8 '24 | Sell | $98.19 | 10,000 | $981,900.00 | 425,162 | SEC Form 4 |
| BIENAIME JEAN JACQUES | BMRN | Director | Dec 21 '23 | Sell | $93.99 | 10,000 | $939,900.00 | 425,112 | SEC Form 4 |
| Davis George Eric | BMRN | EVP, Chief Legal Officer | Dec 13 '23 | Sell | $95.30 | 13,764 | $1,311,709.20 | 55,710 | SEC Form 4 |
Latest BioMarin Pharmaceutical Inc. News
BMRN Breaking Stock News: Dive into BMRN Ticker-Specific Updates for Smart Investing
Motley Fool
2 days ago
4 Incomparable Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
BioPharma Dive
5 days ago
Novo Holdings buys stake in life sciences tools company; BioMarin lays off 170
MT Newswires
7 days ago
Biomarin Pharmaceutical Insider Sold Shares Worth $3,255,200, According to a Recent SEC Filing
PR Newswire
12 days ago
BioMarin to Present at the BofA Securities 2024 Health Care Conference on Wednesday, May 15 at 10:00am PT / 1:00pm ET, in Las Vegas, NV
Zacks
13 days ago
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
GuruFocus.com
14 days ago
Insider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
MT Newswires
14 days ago
Biomarin Pharmaceutical Insider Sold Shares Worth $414,550, According to a Recent SEC Filing
Zacks
14 days ago